Navigation Links
Ultragenyx Relocates Company Headquarters to Support Operational Expansion

NOVATO, Calif., April 23, 2012 /PRNewswire/ -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that it has moved its corporate headquarters to a larger facility in the Bel Marin Keys area of Novato, CA.  The relocation will accommodate current and future growth of Ultragenyx' staff and expand operations in the areas of clinical development, regulatory affairs, technical operations, and administration.  The company will continue to lease laboratory facilities at the Buck Institute in Novato which currently houses the company's research staff.

"Our move to our new corporate headquarters will enable us to support the advancement of our pipeline of treatments for rare and ultra-rare diseases and grow our team as needed," said Emil Kakkis, MD, PhD, Chief Executive Officer, who founded Ultragenyx in 2010.  "We want to express our appreciation to the elected officials and city of Novato for their support of Ultragenyx, and we look forward to continuing to be an integral part of the Novato community."

Ultragenyx will celebrate the relocation of its corporate headquarters by holding a ribbon-cutting ceremony on Friday, April 27, 2012, at 3:30pm at its new location. 

The address of the new corporate headquarters is 60 Leveroni Court, Novato, CA 94949, and the new corporate phone number is 415-483-8800.

About Ultragenyx

Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan and ultra-orphan diseases, to market.  The company focuses on rare metabolic diseases that affect small numbers of patients, but for which the unmet medical need is high and there are no effective treatments.  Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these underserved diseases.  Ultragenyx' lead program, UX001, is being evaluated as a potential treatment for hereditary inclusion body myopathy (HIBM), also known as GNE myopathy. 

The company is led by an experienced management team in rare disease therapeutics.  Ultragenyx is striving toward an improved model for successful rare disease drug development which has the potential to increase efficiency while maintaining appropriate safety and efficacy standards.  The company believes that it can deliver significant value to patients by building a high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine.

For more information on Ultragenyx, please visit the company's website at

SOURCE Ultragenyx Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
2. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
3. Ultragenyx Granted Orphan Drug Designation for UX001 SA-ER for the Treatment of Hereditary Inclusion Body Myopathy (HIBM)
4. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
5. TheraBiogen, Inc. Relocates Corporate Headquarters to New Jersey
6. Rochester Medical Implants Relocates to New Facility in Noblesville, IN
7. The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh
8. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
9. KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard
10. Puritan Medical Products Company Launches New Diagnostic Collection and Transport Systems
11. Global Fund Celebrates Efforts of Partners Chevron, The Coca-Cola Company, (RED) and PEPFAR at Capitol Hill Event
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Indosoft Inc., ... inclusion of an application server to improve system efficiency and reliability. , The new ... many of these standards, the system avoids locking itself into a specific piece of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... ... Finnleo, a leader in the traditional and far-infrared sauna industry, announced a sale ... , For traditional saunas, Finnleo is offering 20% off all Nordic Spruce ... only European Grade A Nordic White Spruce from sustainably grown trees. Because of the ...
Breaking Medicine News(10 mins):